Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury

NCT02001363 · Unknown status

Last updated 2026-05-28

This clinical trial is testing whether a medication called glucagonlike peptide-1 can help reduce heart damage in adults who have just experienced a heart attack.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 90 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2013-11 · est. completion 2016-03

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT02001363 ↗

Description as written by the study sponsor.

The investigators planned to research the cardioprotective effects of intravenous liraglutide on reperfusion injury.

Treatments tested

liraglutide (Novo Nordisk, Bagsværd, Denmark) Drug

once-daily subcutaneous liraglutide 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide 1.2 mg for 2 days ,once-daily subcutaneous liraglutide 1.8 mg for 3 days
liraglutide placebo (Novo Nordisk) Drug

once-daily subcutaneous liraglutide placebo 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide placebo 1.2 mg for 2 days ,once-daily subcutaneous liraglutide placebo 1.8 mg for 3 days

Main thing measured	the salvage index measured by cardiac magnetic resonance
Sponsor	Chen Wei Ren, MD
Conditions studied	Acute Myocardial Infarction
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02001363 ↗